The introduction of new treatments in diabetes, including injectable non-insulin glycemic modulators, creates new opportunities.
The position of GLP1-RA agents in current Australian diabetes treatment algorithms requires GPs to re-think traditional models, including the role of these agents in combination with metformin or as an adjunct to other established treatments.
This program is supported by an independent educational grant provided from Eli Lilly.